Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism

Nanomedicine

Volumn 10, Issue 8, 2015, Pages 1289-1314

  Gupta, Isha ^a,b   Sehgal, Rakesh ^b   Kanwar, Rupinder K ^a   Punj, Vasu ^c   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

lactoferrin; miRNA; oral nanodelivery; Salmonella typhimurium infected; targeted nanodelivery

Indexed keywords

ALGINIC ACID; CIPROFLOXACIN; IRON; LACTOFERRIN; MICRORNA; NANOCAPSULE; NANOCARRIER; ANTIINFECTIVE AGENT; CALCIUM; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CALCIUM METABOLISM; CERAMICS; CONTROLLED STUDY; DRUG EFFICACY; ENDOCYTOSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; IRON METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SALMONELLOSIS; WEIGHT CHANGE; ZINC METABOLISM; ANIMAL; BAGG ALBINO MOUSE; BOVINE; CHEMISTRY; DRUG EFFECTS; METABOLISM; SALMONELLA INFECTIONS;

ANIMALS; ANTI-INFECTIVE AGENTS; CALCIUM; CATTLE; FEMALE; IRON; LACTOFERRIN; MICE; MICE, INBRED BALB C; NANOCAPSULES; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; ZINC;

EID: 84929087151     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.209     Document Type: Article

References (94)

1. Foley SL, White DG, McDermott PF et al. Comparison of subtyping methods for differentiating Salmonella enterica serovar typhimurium isolates obtained from food animal sources. J. Clin. Microbiol. 44(10), 3569-3577 (2006).
2. Mosquito S, Ochoa TJ, Cok J, Cleary TG. Effect of bovine lactoferrin in Salmonella ser. typhimurium infection in mice. Biometals 23(3), 515-521 (2010).
3. Voetsch AC, Van Gilder TJ, Anqulo FJ et al. FoodNet estimate of the burden of illness caused by nontyphoidalsalmonella infections in the United States. Clin. Infect. Dis. 38, 127-134 (2004).
4. Liu C, Stirzaker S, Knuckey D et al. Australia's notifiable disease status, 2007: annual report of the National Notifiable Diseases Surveillance System. Commun. Dis. Intell. 33(2), 89-154 (2009).
5. Diridl G, Pichler H, Wolf D. Treatment of chronic Salmonella carriers with ciprofloxacin. Eur. J. Clin. Microbiol. 5(2), 260-261 (1986).
6. Pichler H, Diridl G, Wolf D. Ciprofloxacin in the treatment of acute bacterial diarrhea: a double blind study. Eur. J. Clin. Microbiol. 5(2), 241-243 (1986).
7. Piddock Lj. Multidrug-resistance efflux pumps-not just for resistance. Nat. Rev. Microbiol. 4(8), 629-636 (2006).
8. Brunner H, Zeiler HJ. Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice. Antimicrob. Agents Chemother. 32(1), 57-62 (1988).
9. Shinagawa N, Hirata K, Katsuramaki T et al. [Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents-special references to bacteria isolated between April 2003 and March 2004]. Jpn. J. Antibiot. 58(2), 123-158 (2005).
10. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 354(9187), 1327-1330 (1999).
11. Rishi P, Mavi SK, Bharrhan S, Shukla G, Tewari R. Protective efficacy of probiotic alone or in conjunction with a prebiotic in Salmonella-induced liver damage. FEMS Microbiol. Ecol. 69(2), 222-230 (2009).
12. Rishi P, Preet S, Kaur P: Effect of L. plantarum cell-free extract and co-trimoxazole against Salmonella typhimurium: a possible adjunct therapy. Ann. Clin. Microbiol. Antimicrob. 10, 9 (2011).
13. Kanwar JR, Kanwar RK, Sun X et al. Molecular and biotechnological advances in milk proteins in relation to human health. Curr. Protein Pept. Science 10(4), 308-338 (2009).
14. Gupta I, Sehgal R, Kanwar RK, Sehgal A, Kanwar JR. Recent advances of metal binding protein lactoferrin as an anti-microbial agent. Curr. Bioactive Compounds 5(3), 226-233 (2009).
15. Bullen JJ. Iron-binding proteins and other factors in milk responsible for resistance to Escherichia coli. Ciba Found. Symp. (42), 149-169 (1976).
16. Murdock CA, Cleveland J, Matthews KR, Chikindas ML. The synergistic effect of nisin and lactoferrin on the inhibition of Listeria monocytogenes and Escherichia coli O157:H7. Lett. Appl. Microbiol. 44(3), 255-261 (2007).
17. Drago-Serrano ME, Rivera-Aguilar V, Resendiz-Albor AA, Campos-Rodriguez R. Lactoferrin increases both resistance to Salmonella typhimurium infection and the production of antibodies in mice. Immunol. Lett. 134(1), 35-46 (2010).
18. Mastroeni P, Clare S, Khan S et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect. Immun. 67(2), 478-483 (1999).
19. Ranjan A, Pothayee N, Seleem Mn et al. Nanomedicine for intracellular therapy. FEMS Microbiol. Lett. 332(1), 1-9 (2012).
20. Kanwar JR, Mahidhara G, Kanwar RK. Novel alginateenclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine 7(10) 1521-1550 (2012).
21. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 30(19), 3297-3306 (2009).
22. Zhang L, Sun M, Guo R et al. Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across Caco-2 cell monolayer. J. Nanosci. Nanotechnol. 6(9-10), 2912-2920 (2006).
23. Benny O, Fainaru O, Adini A et al. An orally delivered smallmolecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 26(7), 799-807 (2008).
24. Samarasinghe RM, Kanwar RK, Kanwar JR. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials 35(26), 7522-7534 (2014).
25. Samarasinghe RM, Kanwar RK, Kumar K, Kanwar JR. Antiarthritic and chondroprotective activity of Lakshadi Guggul in novel alginate-enclosed chitosan calcium phosphate nanocarriers. Nanomedicine 9(6), 819-837 (2014).
26. Kanwar JR, Samarasinghe RM, Sehgal R, Kanwar RK. Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases. J. Cancer Sci. Ther. 4(3), 31-42 (2012).
27. Samarasinghe RM, Kanwar RK, Kanwar JR. The role of nanomedicine in cell based therapeutics in cancer and inflammation. Int. J. Mol. Cell. Med. 1(3), 133-144 (2012).
28. Sofi MH, Bhatnagar A, Sapra S, Mahmood A, Majumdar S. Immunoregulatory role of intestinal surfactant-like particles during Salmonella typhimurium infection. Int. J. Biol. Sci. 3(7), 446-454 (2007).
29. Zhang S, Kingsley RA, Santos RL et al. Molecular pathogenesis of Salmonella enterica serotype typhimuriuminduced diarrhea. Infect. Immun. 71(1), 1-12 (2003).
30. Allen CA, Fedorka-Cray PJ, Vazquez-Torres A et al. In vitro and in vivo assessment of Salmonella enterica serovar typhimurium DT104 virulence. Infect. Immun. 69(7), 4673-4677 (2001).
31. Sukupolvi S, Edelstein A, Rhen M, Normark SJ, Pfeifer JD. Development of a murine model of chronic Salmonella infection. Infect. Immun. 65(2), 838-842 (1997).
32. Lockman HA, Curtiss R 3rd. Salmonella typhimurium mutants lacking flagella or motility remain virulent in BALB/c mice. Infect. Immun. 58(1), 137-143 (1990).
33. Hohmann AW, Schmidt G, Rowley D. Intestinal colonization and virulence of Salmonella in mice. Infect. Immun. 22(3), 763-770 (1978).
34. Kanwar JR, Mahidhara G, Roy K et al. Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine (Lond.) 10(1), 35-55 (2014).
35. Crump JA, Kretsinger K, Gay K et al. Clinical response and outcome of infection with Salmonella enterica serotype typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob. Agents Chemother. 52(4), 1278-1284 (2008).
36. Al-Mashhadani M, Hewson R, Vivancos R et al. Foreign travel and decreased ciprofloxacin susceptibility in Salmonella enterica infections. Emerg. Infect. Dis. 17(1), 123-125 (2011).
37. Parry CM, Vinh H, Chinh NT et al. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar typhi on the clinical response to ofloxacin therapy. PLoS Negl. Trop. Dis. 5(6), e1163 (2011).
38. Boesman-Finkelstein M, Finkelstein RA. Antimicrobial effects of human milk: Inhibitory activity on enteric pathogens. FEMS Microbiol. Lett. 27(2), 167-174 (1985).
39. Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG. Lactoferrin protects rabbits from Shigella flexneriinduced inflammatory enteritis. Infect. Immun. 70(12), 7050-7053 (2002).
40. Ochoa TJ, Brown EL, Guion CE, Chen JZ, McMahon RJ, Cleary TG. Effect of lactoferrin on enteroaggregative E. coli (EAEC). Biochem. Cell Biol. 84(3), 369-376 (2006).
41. Ellison RT 3rd, Giehl TJ. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88(4), 1080-1091 (1991).
42. Goldoni P, Sinibaldi L, Valenti P, Orsi N. Metal complexes of lactoferrin and their effect on the intracellular multiplication of Legionella pneumophila. Biometals 13(1), 15-22 (2000).
43. Naidu SS, Svensson U, Kishore AR, Naidu AS. Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium. Antimicrob. Agents Chemother. 37(2), 240-245 (1993).
44. Appelmelk BJ, An YQ, Geerts M et al. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62(6), 2628-2632 (1994).
45. Bessler HC, De Oliveira IR, Giugliano LG. Human milk glycoproteins inhibit the adherence of Salmonella typhimurium to HeLa cells. Microbiol. Immunol. 50(11), 877-882 (2006).
46. Tomita M, Takase M, Wakabayashi H, Bellamy W. Antimicrobial peptides of lactoferrin. Adv. Exp. Med. Biol. 357, 209-218 (1994).
47. Tian H, Maddox IS, Ferguson LR, Shu Q. Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. Biometals 23(3), 593-596 (2010).
48. Griffiths EA, Duffy LC, Schanbacher FL et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig. Dis. Sci. 49(4), 579-589 (2004).
49. Fischer R, Debbabi H, Blais A et al. Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int. Immunopharmacol. 7(10), 1387-1393 (2007).
50. Worley MJ, Nieman GS, Geddes K, Heffron F. Salmonella typhimurium disseminates within its host by manipulating the motility of infected cells. Proc. Natl Acad. Sci. USA 103(47), 17915-17920 (2006).
51. Ebrahim F, Shankaranarayanan JS, Kanwar JR, Gurudevan S, Krishnan UM, Kanwar RK. Identification of unprecedented anticancer properties of high molecular weight biomacromolecular complex containing bovine lactoferrin (HMW-bLf ). PLoS ONE 9(9), e106568 (2014).
52. Tsuda N, Nonaka Y, Shichijo S et al. UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour. Br. J. Cancer 87(9), 1006-1012 (2002).
53. Iigo M, Alexander DB, Long N et al. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie 91(1), 86-101 (2009).
54. Kanwar JR, Palamo KP, Sun X et al. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol. Cell Biol. 86(3), 277-288 (2008).
55. Chalkley LJ, Koornhof HJ. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob. Agents Chemother. 28(2), 331-342 (1985).
56. Zagulski T, Jarzabek Z, Zagulska A, Zimecki M. The main systemic, highly effective, and quickly acting antimicrobial mechanisms generated by lactoferrin in mammals in vivo. Activity in health and disease. Adv. Exper. Med. Biol. 443, 247-250 (1998).
57. Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP. Lactoferrin protects neonatal rats from gutrelated systemic infection. Am. J. Physiol. Gastrointest. Liver Physiol. 281(5), G1140-1150 (2001).
58. Nilsson AI, Kugelberg E, Berg OG, Andersson DI. Experimental adaptation of Salmonella typhimurium to mice. Genetics 168(3), 1119-1130 (2004).
59. Vidal S, Tremblay ML, Govoni G et al. The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J. Exp. Med. 182(3), 655-666 (1995).
60. Sansonetti PJ. War and peace at mucosal surfaces. Nat. Rev. Immunol. 4(12), 953-964 (2004).
61. Vazquez-Torres A, Jones-Carson J, Baumler AJ et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature 401(6755), 804-808 (1999).
62. Haraga A, Ohlson MB, Miller SI. Salmonellae interplay with host cells. Nat. Rev. Microbiol. 6(1), 53-66 (2008).
63. Kanwar R, Kanwar J. Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein Pept. Lett. 20(4), 450-458 (2013).
64. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int. J. Exp. Pathol. 74(5), 433-439 (1993).
65. Zimecki M, Właszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M. Lactoferrin regulates the immune responses in post-surgical patients. Arch. Immunol. Ther. Exp. (Warsz.) 49(4), 325 (2001).
66. Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A. Activation of macrophages by lactoferrin: secretion of TNF-α, IL-8 and NO. Biochem. Mol. Biol. Int. 43(1), 79-87 (1997).
67. Kruzel M, Harari Y, Mailman D, Actor J. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol. 130(1), 25-31 (2002).
68. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19(5), 641-644 (2003).
69. Galdiero F, de L'ero GC, Benedetto N, Galdiero M, Tufano MA. Release of cytokines induced by Salmonella typhimurium porins. Infect. Immun. 61(1), 155-161 (1993).
70. Kincy-Cain T, Clements JD, Bost KL. Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infect. Immun. 64(4), 1437-1440 (1996).
71. Umezawa K, Akaike T, Fujii S et al. Induction of nitric oxide synthesis and xanthine oxidase and their roles in the antimicrobial mechanism against Salmonella typhimurium infection in mice. Infect. Immun. 65(7), 2932-2940 (1997).
72. Mastroeni P, Clare S, Khan S et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect. Immun. 67(2), 478-483 (1999).
73. Brumme S, Arnold T, Sigmarsson H et al. Impact of Salmonella typhimurium DT104 virulence factors invC and sseD on the onset, clinical course, colonization patterns and immune response of porcine salmonellosis. Vet. Microbiol. 124(3), 274-285 (2007).
74. Yang XO, Chang SH, Park H et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205(5), 1063-1075 (2008).
75. Dong C. Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8(5), 337-348 (2008).
76. Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs Th17 cell differentiation. Nature 458(7234), 78-82 (2009).
77. Mittrucker H-W, Kaufmann SH. Immune response to infection with Salmonella typhimurium in mice. J. Leuk. Biol. 67(4), 457-463 (2000).
78. Kanwar JR, Mahidhara G, Kanwar RK. MicroRNA in human cancer and chronic inflammatory diseases. Front Biosci. (Schol. Ed.) 2, 1113-1126 (2009).
79. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol. Rev. 91(3), 827-887 (2011).
80. Liao Y, Du X, Lonnerdal B. miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J. Nutr. 140(9), 1552-1556 (2010).
81. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 71(4), 1368-1383 (1993).
82. Idzerda RL, Huebers H, Finch CA, Mcknight GS. Rat transferrin gene expression: tissue-specific regulation by iron deficiency. Proc. Natl Acad. Sci. USA 83(11), 3723-3727 (1986).
83. Gunshin H, Mackenzie B, Berger UV et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388(6641), 482-488 (1997).
84. Knutson MD. Iron-sensing proteins that regulate hepcidin and enteric iron absorption. Ann. Rev. Nutr. 30, 149-171 (2010).
85. Kawabata H, Yang R, Hirama T et al. Molecular cloning of transferrin receptor 2 A new member of the transferrin receptor-like family. J. Biol. Chem. 274(30), 20826-20832 (1999).
86. Qiao A, Khechaduri A, Mutharasan RK, Wu R, Nagpal V, Ardehali H. MicroRNA-210 decreases heme levels by targeting ferrochelatase in cardiomyocytes. J. Am. Heart Assoc. 2(2), e000121 (2013).
87. Fierer J, Hatlen L, Lin JP, Estrella D, Mihalko P, Yau-Young A. Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrob. Agents Chemother. 34(2), 343-348 (1990).
88. Prior S, Gamazo C, Irache JM, Merkle HP, Gander B. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. Int. J. Pharm. 196(1), 115-125 (2000).
89. Mingeot-Leclercq MP, Brasseur R, Schanck A. Molecular parameters involved in aminoglycoside nephrotoxicity. J. Toxicol. Environ. Health 44(3), 263-300 (1995).
90. Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 3(3), 239-243 (2007).
91. De Steenwinkel JEM, Van Vianen W, Marian T et al. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. J. Antimicrob. Chemother. 60(5), 1064-1073 (2007).
92. Abrahams GL, Hensel M. Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells. Cell. Microbiol. 8(5), 728-737 (2006).
93. Lecaroz C, Gamazo C, Blanco-Prieto MJ. Nanocarriers with gentamicin to treat intracellular pathogens. J. Nanosci. Nanotechnol. 6(9-10), 3296-3302 (2006).
94. Martínez-Gutierrez F, Thi EP, Silverman JM et al. Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles. Nanomedicine 8(3), 328-336 (2012).